1-5 of 5
Gabriele Fendrich
Close
Sort by
Journal Articles

Fingolimod (FTY720) Inhibits BCR-ABL Signaling Allosterically by Binding to the Myristate Binding Site

Paul W. Manley, Ph. D., Sandra W. Cowan-Jacob, Robert Cozens, Gabriele Fendrich, Wolfgang Jahnke, Johannes L Roesel, Doriano Fabbro
Journal: Blood
Blood (2011) 118 (21): 2746.
https://doi.org/10.1182/blood.V118.21.2746.2746
Published: 2011
Journal Articles

Nilotinib, in Comparison to Both Dasatinib and Imatinib, Possesses a Greatly Prolonged Residence Time When Bound to the BCR-ABL Kinase SH1 Domain

Paul W. Manley, Ph. D., Sandra W. Cowan-Jacob, Gabriele Fendrich, Wolfgang Jahnke, Doriano Fabbro
Journal: Blood
Blood (2011) 118 (21): 1674.
https://doi.org/10.1182/blood.V118.21.1674.1674
Published: 2011
Journal Articles

Bcr-Abl Binding Modes of Dasatinib, Imatinib and Nilotinib: An NMR Study.

Paul W. Manley, Sandra W. Cowan-Jacob, Gabriele Fendrich, André Strauss, Navratna Vapai, Stephan Grzesiek, Wolfgang Jahnke
Journal: Blood
Blood (2006) 108 (11): 747.
https://doi.org/10.1182/blood.V108.11.747.747
Published: 2006
Journal Articles

Molecular Interactions between the Highly Selective pan-Bcr-Abl Inhibitor, AMN107, and the Tyrosine Kinase Domain of Abl.

Paul W. Manley, Sandra W. Cowan-Jacob, Gabriele Fendrich, Jürgen Mestan
Journal: Blood
Blood (2005) 106 (11): 3365.
https://doi.org/10.1182/blood.V106.11.3365.3365
Published: 2005
Journal Articles

AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.

James D. Griffin, MD, Doriano Fabbro, PhD, Gabriele Fendrich, PhD, Brian Huntly, MD, PhD, Sandra Jacob, PhD, Andrew Kung, MD, PhD, Jurgen Mestan, PhD, Ellen Weisberg, PhD, D. Gary Gilliland, MD, PhD, Paul W. Manley, PhD
Journal: Blood
Blood (2004) 104 (11): 551.
https://doi.org/10.1182/blood.V104.11.551.551
Published: 2004